This analysis examines the current position and future outlook for Dainippon Sumitomo in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to order your copy: -Benchmark Dainippon Sumitomos performance against key rivals in the ethical pharmaceutical sector -Evaluate the corporate impact of the merger of Dainippon and Sumitomo -Investigate what strategies are open for Dainippon Sumitomo to build growth in the face of its mature portfolio and weak pipeline
